Differential diagnosis: Hyperplasialesion is small
Think of it as flipping a switch on fat cells that tells them to release their contents
Prescritores e farmacuticos que desejarem obter mais informaes sobre os nossos insumos podem entrar em contato com o nosso SAC por meio do e-mail [email protected] ou pelo 0800 001 1313
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Best before: date on the package Store in a cool, dry place after opening
Hin nay, mi trng ngy cng nhim v cuc sng bn rn dn n stress oxy ha din ra hng ngy, d gy ra gc t do xu cho c th
